

院長 北出光輝業績【主要論文】

タイトル	共同演者	年	雑誌名	巻・号	出版社	編集	学位論文
重症肝炎を来したカルバマゼピンによるhypersensitivity syndromeの1例	相澤茂幸、吉治仁志、小島秀之、伯耆徳之、森田誠司、北出光輝、石川昌利、小林信彦、柴垂伊子、宮川幸子、福井博	2002.	肝臓	43(9):400-405			
Combination of interferon- β and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis	Noguchi R, Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Mitoro A, Tsujinoue H, Imazu H, Masaki T, Fukui H	2003.12 . 1	Clinical Cancer Research	9:6038-6045			学位論文
Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development	Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Namisaki T, Kitade M, Yamazaki M, Tsujinoue H, Masaki T, Fukui H	2004.	Jouranal of Hepatology	41:97-103			
Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice.	Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Hicklin DJ, Wu Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Tsujinoue H, Imazu H, Masaki T, Fukui H	2004.	Hepatology	39(6):1517-1524			
Successful treatment of acute Budd-Chiari syndrome with percutaneous transluminal	Shirai Y, Yoshiji H, Fujimoto M, Kojima H, Yanase K, Namisaki T, Kitade M, Yamamoto K, Sakaguchi H, Kichikawa K, Namisaki T, Yoshiji H, Fujimoto T, Kojima H, Yanase K, Kitade M, Ikenaka Y, Toyohara M, Yamao J, Tsujimoto T, Tsuruzono T, Kitano H, Matsumura K,	2004. 7.	Abdom Imaging	29(6):685-687			
Two cases of colonic tuberculosis presenting with massive melena	H, Yanase K, Kitade M, Ikenaka Y, Toyohara M, Yamao J, Tsujimoto T, Tsuruzono T, Kitano H, Matsumura K,	2004.12 .	Int J Clin Pract	58(12):1162-1164			
PDGFを分子標的とした肝線維化治療の基礎的検討	吉治仁志、池中英、吉井純一、野口隆一、浪崎正、北出光輝、築瀬公嗣、山崎正晴、福井博	2005.	薬理と治療	33:S91-S95	ライフサイエンス		
Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice	Yoshiji H, Noguchi R, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Fukui H	2005.	Oncology Reports	13:491-495			
Different cascades in the signaling pathway of two vascular endothelial growth factor(VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma	Yoshiji H, Noguchi R, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Uemura M, Fukui H	2005.	Oncology Reports	13:853-857			
Imatinib mesylate(STI-571) attenuates liver fibrosis development in rats	Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, Yanase K, Namisaki T, Kitade M, Masaki T, Fukui H	2005.	Am J Physiol Gastrointest Liver Physiol	288:G907-913			
Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression	Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Masaki T, Fukui H	2005.	Journal of Hepatology	42:687-693			
Combination of copper-chelating agent, trientine, and methorexate attenuates colorectal carcinoma development and angiogenesis in	Yoshiji H, Yoshii J, Kuriyama S, Ikenaka Y, Noguchi R, Yanase K, Namisaki T, Kitade M, Yamazaki M, Fukui H	2005.	Oncology Reports	14:213-218			
Suppression of Renin-Angiotensin System Attenuates Hepatocarcinogenesis Via Angiogenesis Inhibition in Rats	Yoshiji H, Noguchi R, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Uemura M, Fukui H	2005.	Anticancer Research	25:3335-3340			
Intrahepatic Cholangiocarcinoma Associated with Central Calcification and Arterio-portal	Kitade M, Yoshiji H, Yamao J, Fujimoto M, Kojima H, Mitoro A, Yoshida M, Namisaki T, Yamazaki M, Toyohara M, Uemura M,	2005. 8.	Internal Medicine	44(8):825-828			
Angiopietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma	Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Uemura M, Masaki T, Fukui H	2005.12 .	GUT	54:1768-1775			
Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF- β with a combination of imatinib mesylate and ACE inhibitor in rats	Yoshiji H, Kuriyama S, Noguchi R, Ikenaka Y, Yoshii J, Yanase K, Namisaki T, Kitade M, Yamazaki M, Asada K, Akahane T, Tsujimoto T, Uemura M, Fukui H	2006.	International Journal of Molecular Medicine	17:899-904			

Salvage effect of the vascular endothelial growth factor on chemically induced acute severe liver injury in rats.	Namisaki T, Yoshiji H, Kojima H, Yoshii J, Ikenaka Y, Noguchi R, Sakurai S, Yanase K, Kitade M, Yamazaki M, Asada K, Uemura M, Nakamura M, Fukui H	2006.	Journal of Hepatology	44:568-575			学位論文
Angiotensin- II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development	Yoshiji H, Kuriyama S, Noguchi R, Ikenaka Y, Kitade M, Kaji K, Yoshii J, Yanase K, Yamazaki M, Asada K, Tsujimoto T, Akahane T, Uemura M, Fukui H	2006.	Hepatology Research	36:124-129			
A potent angiogenic factor, vascular endothelial growth factor, improves the survival of the on-going acute hepatic failure in rats	Namisaki T, Yoshiji H, Kuriyama S, Kojima H, Yoshii J, Ikenaka Y, Noguchi R, Sakurai S, Yanase K, Kitade M, Yamazaki M, Asada K, Tsujimoto T, Akahane T, Uemura M, Fukui H	2006.	Hepatology Research	35:199-203			
Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats	Noguchi R, Kaji K, Yoshii J, Yanase K, Namisaki T, Asada K, Yamazaki M, Tsujimoto T, Akahane T, Uemura M, Fukui H	2006.	Hepatology	44(4):983-991			
Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic	Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Akahane T, Asada K, Tsujimoto T, Uemura M, Kuriyama S	2006.	Oncology Reports	15:155-159			
Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic	Yoshiji H, Noguchi R, Kojima H, Ikenaka Y, Kitade M, Kaji K, Uemura M, Yamao J, Fujimoto M, Yamazaki M, Toyohara M, Mitoro A, Fukui H	2006.11	World Journal of Gastroenterology	12(42):6786-6791			
Vitamin K2の抗血管新生作用に基づく肝発癌抑制効果：ACE阻害剤との併用を含めて	吉治仁志、吉井純一、池中康英、野口隆一、築瀬公嗣、浪崎正、北出光輝、山崎正晴、浅田潔、福井博	2006.11.30	第9回 Vitamin K & Aging 研究会記録集	P117-122			折茂 肇
11. 劇症肝炎ラットモデルにおける血管新生因子 Vascular Endothelial Growth Factor(VEGF)の救命効果と作用機序	浪崎正、吉治仁志、池中康英、野口隆一、北出光輝、鍛治孝祐、吉井純一、築瀬公嗣、山崎正晴、浅田潔、辻本達寛、福井博	2006.12.15	薬理と治療	34:S155-S159			ライオンサイエンス出版株式会社 Nova Science Publishers
Role of angiogenesis in the development of preneoplastic lesions in hepatocellular carcinoma	Yoshiji H, Kuriyama S, Noguchi R, Ikenaka Y, Kitade M, Kaji K, Uemura M, Fukui H	2007.	New Research on Precancerous Conditions	P121-141			Jennifer E, Litchfield
ラット非アルコール性脂肪性肝炎 (NASH)モデルにおける自然免疫	瓦谷英人、辻本達寛、北澤利幸、北出光輝、吉治仁志、藤本正男、植村正人、福井博、山下奈美子、平井都始子	2007.	アルコールと医学生物学	27:192-196			東洋書店
Renin-Angiotensin system inhibitors as therapeutic alternatives in the treatment of	Yoshiji H, Noguchi R, Ikenaka Y, Kitade M, Kaji K, Tsujimoto T, Uemura M, Fukui H	2007.	Current Medicinal chemistry	14:2749-2754			
ラット非アルコール性脂肪性肝炎 (NASH)モデルにおけるKupffer細胞の貪食能と動態	辻本達寛、瓦谷英人、北澤利幸、北出光輝、吉治仁志、藤本正男、植村正人、福井博、山下奈美子、平井都始子	2007.	アルコールと医学生物学	27:203-208			東洋書店
Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin -converting enzyme inhibitor via anti-angiogenic	Yanase K, Yoshiji H, Ikenaka Y, Noguchi R, Kitade M, Kaji K, Yoshii J, Namisaki T, Yamazaki M, Asada K, Tsujimoto T, Akahane T, Uemura M, Fukui H	2007.	Oncology Reports	17(2):441-446			
Crosstalk between high-molecular-weight adiponectin and T-cadherin during liver fibrosis development in rats	Asada K, Yoshiji H, Noguchi R, Ikenaka Y, Kitade M, Kaji K, Yoshii J, Yanase K, Namisaki T, Yamazaki M, Tsujimoto T, Akahane T, Uemura M, Fukui H	2007.	International Journal of molecular medicine	20:725-729			
NASH進展過程における血管新生の役割：Zuckerラットを用いた検討	吉治仁志、北出光輝、池中康英、野口隆一、鍛治孝祐、福井博	2007. 3.	Minophagen Medical Review	52(3):83-84			
Combined treatment of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis	Yoshiji H, Noguchi R, Yamazaki M, Ikenaka Y, Sawai M, Ishikawa M, Kawaratani H, Mashitani T, Kitade M, Kaji K, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Yoshida M, Fukui H	2007. 6.	World Journal of Gastroenterology	13(23):3259-3261			
Eosinophilic cholecystitis along with pericarditis caused by Ascaris lumbricoides: A case report	Kaji K, Yoshiji H, Yoshikawa M, Yamazaki M, Ikenaka Y, Noguchi R, Sawai M, Ishikawa M, Mashitani T, Kitade M, Kawaratani H, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M	2007. 7.21	World Journal of Gastroenterology	13(27)3760-3762			

15. NASHにおける肝線維化進展と血管新生および酸化ストレスの関係—ラットNASHモデルおよび肝生検組織を用いた検討—	北出光輝、吉治仁志、池中英、野口隆一、鍛治孝祐、吉井純一、築瀬公嗣、浅田潔、山崎正晴、福井博	2007.12.15	薬理と治療	35:S261-S266		
9. 血管新生を標的とした肝発癌予防のトランスレーショナルリサーチ—ACE阻害剤とビタミンK投与の試み—	吉治仁志、野口隆一、池中英、北出光輝、鍛治孝祐、浅田潔、山崎正晴、吉井純一、築瀬公嗣、浪崎正、福井博	2007.12.15	薬理と治療	35:S225-S230		
Different tumoricidal effects of interferon subclasses and p53 status on hepatocellular carcinoma development and	Noguchi R, Yoshiji H, Ikenaka Y, Kitade M, Kaji K, Yoshii J, Yanase K, Namisaki T, Yamazaki M, Tsujimoto T, Akahane T, Uemura M, Fukui H	2008.	International Journal of Oncology	32:193-199		
Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis	Kitade M, Yoshiji H, Kojima H, Ikenaka Y, Noguchi R, Kaji K, Yoshii J, Yanase K, Namisaki T, Yamazaki M, Tsujimoto T, Moriya K, Kawaratani H, Akahane T, Fukui Kaji K, Yoshiji H, Kitade M, Ikenaka Y,	2008.	Molecular Medicine Reports	1:543-548		
Impact of insulin resistance on the progression of chronic liver diseases	Noguchi R, Yoshii J, Yanase K, Namisaki T, Yamazaki M, Moriya K, Tsujimoto T, Kawaratani H, Akahane T, Uemura M,	2008.	International Journal of Molecular Medicine	22:801-808		
最近の薬物性肝障害の多様性：特に自己免疫性肝炎発症との関連について	森岡千恵、榎村正人、守屋圭、山尾純一、藤本正男、吉治仁志、山崎正晴、豊原真久、美登路昭、池中英、榎松由佳子、吉田太之、沢井正佳、辻本達寛、野口隆一、上嶋昌和、増谷剛、石川昌利、北出光輝、瓦谷英人、西尾福真理子、鍛治孝祐、村田早苗、相原洋祐、塩山えりか、佐藤芳樹、松尾憲秀、福井博	2008.10.20	薬物性肝障害の実態	P66-76	中外医学社	滝川一、福井博、堀池典生
Decreased phagocytic activity of kupffer cells in a rat nonalcoholic steatohepatitis model	Tsujimoto T, Kawaratani H, Kitazawa T, Hirai T, Onishi H, Kitade M, Yoshiji H, Uemura M, Fukui H	2008.10.21	World Journal of Gastroenterology	14(39):5945-6108		
Innate immune reactivity of the liver in rats fed a cholinedeficient L-amino-acid-defined diet	Kawaratani H, Tsujimoto T, Kitazawa T, Kitade M, Yoshiji H, Uemura M, Fukui H	2008.11.21	World Journal of Gastroenterology	14(43):6655-6661		
タナパロイドナトリウムによる治療期間中に胃静脈瘤破裂をきたした門脈血栓症の1例	瓦谷英人、松村雅彦、辻本達寛、森本朋子、北出光輝、梅本典江、酒井恭子、福井博	2008.12	日本消化器病学会雑誌	105(12):1758-1765		
内視鏡的硬化療法時の栄養管理における経口特殊アミノ酸製剤の有用性	沢井正佳、松村雅彦、池中英、上嶋昌和、森安博人、梅本典江、森岡千恵、小島邦行、北出光輝、吉田太之、福井博	2009.	栄養—評価と治療	26(5):70-75		
NASH肝発癌過程における血管新生の役割	北出光輝、吉治仁志、鍛治孝祐、池中英、野口隆一、浪崎正、吉井純一、築瀬公嗣、山崎正晴、福井博	2009.	消化器科	48(1):105-112		
Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats	Yoshiji H, Noguchi R, Kitade M, Kaji K, Ikenaka Y, Namisaki T, Yoshii J, Yanase K, Yamazaki M, Tsujimoto T, Akahane T, Kawaratani H, Uemura M, Fukui H	2009.	Journal of Gastroenterology	44(5):483-491		
Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report	Mashitani I, Yoshiji H, Yamazaki M, Ikenaka Y, Noguchi R, Ishikawa M, Kawaratani H, Matsuo N, Uemura M, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Yoshida M, Sawai M, Morioka C, Tsujimoto T, Kitade M, Kaji K, Aihara Y,	2009.	Cases Journal	2(18):1-5		
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities	Noguchi R, Yoshiji H, Ikenaka Y, Namisaki T, Kitade M, Kaji K, Yoshii J, Yanase K, Yamazaki M, Tsujimoto T, Kawaratani H, Fukui H	2009.	Oncology Reports	22:355-360		
Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma	Yoshiji H, Noguchi R, Toyohara M, Ikenaka Y, Kitade M, Kaji K, Yamazaki M, Yamao J, Mitoro A, Sawai M, Yoshida M, Fujimoto M, Tsujimoto T, Kawaratani H, Uemura M,	2009.	Journal of Hepatology	51:315-321		
Losartan, an angiotensin-II type I receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat	Yoshiji H, Noguchi R, Ikenaka Y, Namisaki T, Kitade M, Kaji K, Shirai Y, Yoshii J, Yanase K, Yamazaki M, Tsujimoto T, Kawaratani H, Akahane T, Aihara Y, Fukui H	2009. 5.	BMC Research Notes	2:70	Open Access	
血管新生因子VEGFに対する既存薬剤を用いた分子標的治療の試み：インスリン抵抗性条件下での肝発癌に対するBCAAの効果	吉治仁志、鍛治孝祐、北出光輝、池中英、野口隆一、吉井純一、築瀬公嗣、山崎正晴、浪崎正、福井博	2009.10.9	消化器疾患におけるエピゲノミクスとゲノミクス	P135-136	アーキメディア	小俣政男

内視鏡的硬化療法時の栄養管理における経口特殊アミノ酸製剤の有用性	沢井正佳、松村雅彦、池中康英、上嶋昌和、森安博人、梅本典江、森岡千恵、小島邦行、北出光輝、吉田太之、福井博	2009.10.15	栄養 評価と治療	26(5):430-435		
Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis	Kitade M, Yoshiji H, Noguchi R, Ikenaka Y, Kaji K, Shirai Y, Yamazaki M, Uemura m, Yamao J, Fujimoto M, Mitoro A, Toyohara M, Sawai M, Yoshida M, Morioka C, Tsujimoto T, Kawaratani H, Fukui H	2009.11.7	World Journal of Gastroenterology	15(41):5121-5248		
肝線維化進展・肝発癌過程におけるインスリン抵抗性の関与	鍛冶孝祐、吉治仁志、北出光輝、池中康英、野口隆一、白井勇作、吉井純一、築瀬公嗣、浪崎正、山崎正晴、福井博	2009.12.25	薬理と治療	37(Suppl):107-112	ライフサイエンス	
非アルコール性脂肪肝炎 (nonalcoholic steatohepatitis:NASH)患者における Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in	川島愛子、菅原詩緒理、榊万美子、沖田美佐子、萬谷育子、北出光輝、吉治仁志、福井博、塚本幾代	2010.	日本臨床栄養学会雑誌	31(1.2.3):1-8		
Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats	Yoshiji H, Noguchi R, Kaji K, Ikenaka Y, Shirai Y, Namisaki T, Kitade M, Tsujimoto T, Kawaratani H, Fukui H	2010.	J Gastroenterol	45:443-450		
The vascular endothelial growth factor(VEGF) receptor-2 is a major regulator of VEGF-mediated salvage effect in murine acute	Noguchi R, Yoshiji H, Ikenaka Y, Kaji K, Shirai Y, Aihara Y, Yamazaki M, Namisaki T, Kitade M, Yoshii J, Yanase K, Kawaratani H, Tsujimoto T, Fukui H	2010.	International Journal of Molecular Medicine	26:407-413		
Selective aldosterone blocker, eplerenone, attenuates hepatocellular carcinoma growth and angiogenesis in mice	Namisaki T, Yoshiji H, Noguchi R, Ikenaka Y, Kitade M, Kaji K, Shirai Y, Aihara Y, Yoshii J, Yanase K, Tsujimoto T, Kawaratani H, Fukui H	2010.	Journal of angiogenesis research	2:16		
Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats	Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, Shirai Y, Aihara Y, Namisaki T, Yoshii J, Yanase K, Tsujimoto T, Kawaratani H, Fukui H	2011.	Am J Physiol Gastrointest Liver Physiol	300:G1094-1104		
Dual blockade of angiotensin- II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis	Noguchi R, Yoshiji H, Ikenaka Y, Kaji K, Aihara Y, Shirai Y, Namisaki T, Kitade M, Douhara A, Moriya K, Fukui H	2013.	Hepatology Research	43(7):765-774		
Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance	Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, Douhara A, Yamao J, Fujimoto M, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Uejima M, Uemura M, Fukui H	2013.	Oncology Reports	30:545-552		
METとEGFRはそれぞれ独自のシグナルで肝前駆細胞の分化運命を規定する	北出光輝、吉治仁志、福井博	2013.7.10	分子消化器病学研究会 第20回浜名湖シンポジウム記録集 ゲノム情報の臨床応用	P140-144	株式会社 アークメディア	
Specific fate decisions in adult hepatic progenitor cells driven by MET and EGFR signaling	Kitade M, Factor VM, Andrsen JB, Tomokuni A, Kaji K, Akita H, Holczbauer A, Seo D, Marquardt JU, Conner EA, Lee SB, Lee YH, Thorgeirsson SS	2013.8.	Genes & Development	27(15):1706-1717		
分岐鎖アミノ酸 (BCAA)によるインスリン抵抗性条件下での肝発癌・再発抑制効果：血管新生および酸化ストレスの関与	吉治仁志、野口隆一、相原洋祐、浪崎正、守屋圭、北出光輝、堂原彰敏、福井博	2013.11.12	酸化ストレスと肝疾患 (第9巻)	P11-16	酸化ストレスと肝研究会事務局	坪内博仁
特集 I 高齢化社会におけるNSAID s 消化管障害 COX-2選択性NSAID s による上部消化管障害のリスクファクター	沢井正佳、山尾純一、美登路昭、吉田太之、野口隆一、浪崎正、上嶋昌和、田原一樹、守屋圭、北出光輝、竹田幸祐、瓦谷英人、大倉康志、高谷広章、堂原彰敏、西村典久、澤田保彦、関建一郎、石田光志、吉治仁志、福井博、守屋圭、吉治仁志、堂原彰敏、浪崎正、野口隆一、上嶋昌和、瓦谷英人、相原洋祐、高谷広章、北出光輝、西村典久、関建一郎、賀屋大介、辻裕樹、錦織麻衣子、田原一樹、吉田太之、豊原真久、美登路昭、藤本正男、沢井正佳、山尾純一、福井博	2014.	消化器内科	59(2):123-130		
高齢者進行肝細胞癌の治療選択：ソラフェニブか肝動注化学療法か	上嶋昌和、北出光輝、西村典久、関建一郎、賀屋大介、辻裕樹、錦織麻衣子、田原一樹、吉田太之、豊原真久、美登路昭、藤本正男、沢井正佳、山尾純一、福井博	2014.	日本高齢消化器病学会誌	16(2):26-32		

Combination of sorafenib and angiotensin- II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of	Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, Douhara A, Kawaratani H, Nishimura N, Fukui H	2014.	J Gastroenterol	49:1421-1429		
Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats.	Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Douhara A, Moriya K, Kawaratani H, Shirai Y, Yoshiji H, Yanase K, Kitade M, Namisaki T, Fukui H	2014.	J Gastroenterol.	49(3):481-491		
Impact of a transparent hood on the performance and therapeutic result of endoscopic injection sclerotherapy	Uejima M, Matsumura M, Umemoto N, Yoshida M, Sawai M, Namisaki T, Kitade M, Kawaratani H, Takaya H, Aihara Y, Mitoro A, Yoshiji H, Yamao J, Fukui H	2014.12.31	奈良医学雑誌	65 (4.5.6) : 51-62		学位論文
Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model	Douhara A, Moriya K, Yoshiji H, Noguchi R, Namisaki T, Kitade M, Kaji K, Aihara Y, Nishimura N, Takeda K, Okura Y, Kawaratani H, Fukui H	2015.	Molecular Medicine Reports	11 : 1693-1700		
Gastric adenocarcinoma of fundic gland type (chief cell predominant type) with unique endoscopic appearance curatively treated by endoscopic submucosal resection	Takeda S, Mitoro A, Namisaki T, Yoshida M, Sawai M, Yamao J, Yoshiji H, Uejima M, Moriya K, Douhara A, Seki K, Ishida K, Morita K, Noguchi R, Kitade M, Kawaratani H, Okura Y, Takaya H, Fukui H	2015.	Acta Gastro-Enterologica Belgica.	p 336-339		
当科における肝硬変の成因別実態	藤本正男、吉治仁志、山崎正晴、美登路昭、樽松由佳子、吉田太之、沢井正佳、田原一樹、野口隆一、浪崎正、上嶋昌和、守屋圭、北出光輝、竹田幸祐、福井博	2015. 5. 1	肝硬変の成因別実態	P36-43	2014	医学図書出版株式会社 泉並木
Beneficial effects of combined ursodeoxycholic acid and angiotensin- II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic	Namisaki T, Noguchi R, Moriya K, Kitade M, Aihara Y, Douhara A, Nishimura N, Takeda K, Okura Y, Kawaratani H, Takaya H, Seki K, Yoshiji H	2015. 6.	J Gastroenterol	51(2):162-72		
脂肪性肝炎モデルにおける自然免疫系の解析とサイトカイン産生調整薬による新規治療法の開発	瓦谷英人、野口隆一、守屋圭、浪崎正、北出光輝、竹田幸祐、大倉康志、高谷広章、堂原彰敏、西村典久、藤本正男、吉治仁志、福井博	2015. 9.30	エンドトキシン・自然免疫研究18	P69-72		医学図書出版株式会社
NAFLD/NASH, 肝発癌の機序, 病態	鍛冶孝祐、北出光輝、吉治仁志	2016.	Current Therapy	34(7):684-689		
ダクラタスビル・アスナプレビル併用療法の抑うつに及ぼす影響	竹田幸祐、野口隆一、浪崎正、守屋圭、増谷剛、北出光輝、瓦谷英人、大倉康志、鍛冶孝祐、相原洋祐、西村典久、澤田保彦、佐藤慎哉、関建一郎、美登路昭、吉治仁志	2016.	肝臓	57(9):496-498		
Beneficial effects of combined ursodeoxycholic acid and angiotensin- II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic	Namisaki T, Noguchi R, Moriya K, Kitade M, Aihara Y, Douhara A, Nishimura N, Takeda K, Okura Y, Kawaratani H, Takaya H, Seki K, Yoshiji H	2016.	J Gastroenterol.	51 : 162-172		
The relationship between hepatic progenitor cell-mediated liver regeneration and non-parenchymal cells.	Kitade M, Kaji K, Yoshiji H	2016. 2. 19	Hepato Res.			
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats	Nishimura N, Kitade M, Noguchi R, Namisaki T, Moriya K, Takeda K, Okura Y, Aihara Y, Douhara A, Kawaratani H, Asada K, Yoshiji H	2016. 3. 29	J Gastroenterol.			
非ウイルス性肝硬変に対する治療－肝不全・肝癌への進展をどう抑制するか	鍛冶孝祐、北出光輝、吉治仁志	2016. 6.10	消化器の臨床	19(3):216-221		ヴァンメディカ 桑山肇
硬膜外膿瘍からMSSA菌血症となり食道静脈瘤破裂にいたったアルコール性肝硬変の一例	梶本衣里奈、浪崎正、竹田悠一、澤田保彦、高谷広章、北出光輝、田原一樹、吉治仁志、山尾純一、沢井正佳	2016. 6.30	奈良医学雑誌	67 (1.2.3) : 29-33		
Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model (非アルコール性脂肪肝炎 (NASH) モデルのラットにおいて、エンドトキシンの減少が肝星細胞の活性化抑制と腸管透過性改善	堂原彰敏、守屋圭、野口隆一、浪崎正、北出光輝、相原洋祐、西村典久、瓦谷英人、竹田孝祐、大倉康志、吉治仁志	2016. 7. 1	奈良県医師会医学会年報	29(1):75-80		

DNA methylation of angiotensin II receptor gene in nonalcoholic steatohepatitis-related liver fibrosis	Asada K, Aihara Y, Takaya H, Noguchi R, Namisaki T, Moriya K, Uejima M, Kitade M, Mashitani T, Kakeda K, Kawaratani H, Okura Y, Kaji K, Douhara A, Sawada Y, Nishimura N, Seki K, Mitoro A, Yamao J, Douhara A, Namisaki T, Moriya K, Kitade M, Kaji K, Kawaratani H, Takeda K, Okura Y, Takaya H, Noguchi R, Nishimura N, Seki K, Sato S, Sawada Y, Yamao J, Mitoro A, Uejima M, Mashitani T, Shimozato N, Saikawa S, Nakanishi K, Furukawa M, Kubo T, Takeda K, Noguchi R, Kitade M, Namisaki T, Moriya K, Kawaratani H, Okura Y, Kaji K, Aihara Y, Douhara A, Nishimura N, Sawada Y, Seki K, Yoshiji H	2016.10.8	World J Hepatol	8(28):1194-1199		
Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization	Takaya H, Kawaratani H, Kaneko M, Takeda S, Sawada Y, Kitade M, Moriya K, Namisaki T, Sawai M, Mitoro A, Yamao J, Yoshiji H.	2017.	Oncology Letters	14(3):3028-3034		
Periostin cross-reacts with the renin-angiotensin system during liver fibrosis development.	Kawaratani H, Fukui H, Moriya K, Noguchi R, Namisaki T, Uejima M, Kitade M, Takeda K, Okura Y, Kaji K, Nishimura N, Takaya H, Aihara Y, Sawada Y, Sato S, Seki K, Mitoro A, Yamao J, Yoshiji H.	2017.	Mol Med Rep.	16(5):5752-5758		
Gastric granular cell tumor in a youth excised by endoscopic submucosal dissection : A case report and literature review	Okura Y, Namisaki T, Moriya K, Kitade M, Takeda K, Kaji K, Noguchi R, Nishimura N, Seki K, Kawaratani H, Takaya H, Sato S, Sawada Y, Shimozato N, Furukawa M, Nakanishi K, Saikawa S, Kubo T, Asada K, Yoshiji H	2017.	Acta Gastroenterol Belg	80(2):317-319		
Predictive parameter of tolvaptan effectiveness in cirrhotic ascites	西村典久、北出光輝、吉治仁志	2017.	Hepatol Res.	47(9):854-861		
Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin- II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat	Yoshiji H	2017.	Hepatology Research			学位論文
SGLT2阻害薬のインスリン抵抗性改善作用を介した肝線維化進展抑制作用		2017.	日本門脈圧亢進症学会雑誌	23(2):155-160		
Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis.	Namisaki T, Moriya K, Noguchi R, Kitade M, Kawaratani H, Yamao J, Mitoro A, Yoshida M, Sawai M, Uejima M, Mashitani T, Takeda K, Okura Y, Kaji K, Takaya H, Aihara Y, Douhara A, Nishimura N, Sawada Y, Sato S, Seki K, Yoshiji H	2017.	Hepatol Res.	47(3):E178-E186		
Gastric granular cell tumor in a youth excised by endoscopic submucosal dissection: A case report and literature review	Takaya H, Kawaratani H, Kaneko M, Takeda K, Sawada Y, Kitade M, Moriya K, Namisaki T, Sawai M, Mitoro A, Yamao J, Yoshiji H	2017.	Acta Gastroenterol Belg.	80 : 317-319		
Platelet hyperaggregability is associated with decreased ADAMTS13 activity and enhanced endotoxemia in patients with acute	Takaya H, Kawaratani H, Kubo T, Seki K, Sawada Y, Kaji K, Okura Y, Takeda K, Kitade M, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H.	2017. 6	Hepatol Res.	48(3):E52-E60		
Clinical significance of the Scheuer histological staging system for primary biliary cholangitis in Japanese patients.	Namisaki T, Moriya K, Kitade M, Kawaratani H, Takeda K, Okura Y, Takaya H, Nishimura N, Seki K, Kaji K, Sato S, Sawada Y, Yamao J, Mitoro A, Uejima M, Mashitani T, Shimozato N, Nakanishi K, Furukawa M, Saikawa S, Kubo T, Yoshiji H	2017. 6.	Eur J Gastroenterol Hepatol	29(1):23-30		
Therapeutic strategies for alcoholic liver disease: Focusing on inflammation and fibrosis (Review).	Kawaratani H, Moriya K, Namisaki T, Uejima M, Kitade M, Takeda K, Okura Y, Kaji K, Takaya H, Nishimura N, Sato S, Sawada Y, Seki K, Kubo T, Mitoro A, Namisaki T, Moriya K, Kitade M, Takeda K,	2017. 8.	Int J Mol Med.	40(2):263-270		
Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis.	Kaji K, Okura Y, Shimozato N, Sato S, Nishimura N, Seki K, Kawaratani H, Takaya H, Sawada Y, Akahane T, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Noguchi R, Asada K, Kitagawa K, Ozutsumi T, Tsuji	2017. 9.	Hepatol commun.	1(9) : 928-945		
Serum angiotensin-converting enzyme level for evaluating significant fibrosis in chronic hepatitis B	Noguchi R, Kaji K, Namisaki T, Moriya K, Kitade M, Takeda K, Kawaratani H, Okura Y, Aihara Y, Furukawa M, Mitoro A, Yoshiji H	2017. 9.28	World Journal of Gastroenterology	23 (36) : 6705-6714		

A Patient with Hepatocellular Carcinoma with Isolated Right Atrial Metastases.	Takaya H, Kawaratani H, Seki K, Okura Y, Kitade M, Namisaki T, Sawai M, Sawada Y, Kubo T, Mitoro A, Yamao J, Yoshiji H.	2017.10	Intern Med	56(19):2589-2594		
Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting Angiotensin- II 受容体阻害薬による	Kaji K, Nishimura N, Seki K, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kawaratani H, Kitade M, Moriya K, Namisaki T, Yoshiji H.	2017.12	International Journal of Cancer	4		
Hippo-YAP経路を介した肝内胆管癌抑制効果	才川宗一郎、鍛治孝祐、古川政統、関建一郎、中西啓祐、佐藤慎哉、西村典久、下里直隆、北出光輝、守屋圭、浪崎正、吉治仁志	2017.12	The Liver Cancer Journal	9(2):74-75	メディカルレビュー社	
Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.	Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H.	2017.12	World J Gastroenterol.	23(47):8355-8366		
Short-term sustained virological response in a patient with liver cirrhosis, hepatitis C, and declining hepatic spare ability during treatment with direct-acting antivirals	Mori H, Takaya H, Namisaki T, Noguchi R, Hanatani J, Kaneko M, Seki K, Okura Y, Kitade M, Mitoro A, Yamao J, Yoshiji H	2018.	Nihon Shokakibyo Gakkai Zasshi	115(5):476-484		
当科における肝硬変の成因別実態	藤本正男、吉治仁志、美登路昭、浪崎正、守屋圭、北出光輝、赤羽たけみ、瓦谷英人、鍛治孝	2018.	肝硬変の成因別実態	P114-117	医学図書出版	日本肝臓学会
Treatment of long-segment Barrett's adanocarcinoma by complete circular endoscopic submucosal dissection: a case report.	Kaneko M, Mitoro A, Yoshida M, Sawai M, Okura Y, Furukawa M, Namisaki T, Moriya K, Akahane T, Kawaratani H, Kitade M, Kaji K, Takaya H, Sawada Y, Seki K, Sato S, Fujii T, Yamao J, Obayashi C, Yoshiji H	2018.	BMC Gastroenterol.	18(1):16		
Glycogenic Hepatopathy in Type 1 Diabetes Mellitus	Asada S, Kawaratani H, Mashitani T, Kaya D, Nishigori M, Kubo T, Sawada Y, Fujinaga Y, Kaji K, Kitade M, Namisaki T, Moriya K, Mitoro A, Yoshiji H	2018. 4.	Intern Med.	57 (8) : 1087-1092		
Oral administration of fructose exacerbates liver fibrosis and hepatocarcinogenesis via increased intestinal permeability in a rat steatohepatitis model	Seki K, Kitade M, Nishimura N, Kaji K, Asada K, Namisaki T, Moriya K, Kawaratani H, Okura Y, Takaya H, Sawada Y, Sato S, Nakanishi K, Yoshiji H.	2018. 6.	Oncotarget.	19;9(47):28638-28651.		学位論文
Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.	Moriya K, Namisaki T, Sato S, Douhara A, Furukawa M, Kawaratani H, Kaji K, Kitade M, Shimozato N, Sawada Y, Seki K, Saikawa S, Takaya H, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H.	2018. 8.	J Gastrointest Oncol.	9(4):741-749		
Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis.	Okura Y, Namisaki T, Sato S, Moriya K, Akahane T, Kitade M, Kawaratani H, Kaji K, Takaya H, Sawada Y, Shimozato N, Seki K, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Kaya D, Tsuji Y, Ozutsumi T, Kitagawa K, Mashitani T, Ogawa	2018. 9.	Hepatol Res.			
Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infection.	Takeda K, Noguchi R, Namisaki T, Moriya K, Akahane T, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Fujinaga Y, Tsuji Y, Kubo T, Sato S, Saikawa S, Nakanishi K, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Mitoro A, Mashitani T.	2018. 9.	Exp Ther Med.	16(3):2743-2750		
Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein.	Saikawa S, Kaji K, Nishimura N, Seki K, Sato S, Nakanishi K, Kitagawa K, Kawaratani H, Kitade M, Moriya K, Namisaki T, Mitoro A, Yoshiji H.	2018.10	Cancer Letters	434:120-129		

von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C. Acyclic	Takaya H, Kawaratani H, Tsuji Y, Nakanishi K, Saikawa S, Sato S, Sawada Y, Kaji K, Okura Y, Shimozato N, Kitade M, Akahane T, Moriya K, Namisaki T, Mitoro A, Matsumoto M, Fukui H, Yoshiji H	2018.11	United European Gastroenterol J.	6(9):1401-1409	
retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats.	Nishimura N, Kaji K, Kitade M, Aihara Y, Sato S, Seki K, Sawada Y, Takaya H, Okura Y, Kawaratani H, Moriya K, Namisaki T, Mitoro A, Yoshiji H	2018.11	BMC Cancer.	18(1):1164.	
Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis.	Okura Y, Namisaki T, Sato S, Moriya K, Akahane T, Kitade M, Kawaratani H, Kaji K, Takaya H, Sawada Y, Shimozato N, Seki K, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Kaya D, Tsuji Y, Ozutsumi T, Kitagawa K, Mashitani T, Ogawa H, Ishida K, Mit	2019. 2.	Hepatol Res.	49(2):232-238	
Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.	Sawada Y, Kawaratani H, Kubo T, Fujinaga Y, Furukawa M, Saikawa S, Sato S, Seki K, Takaya H, Okura Y, Kaji K, Shimozato N, Mashitani T, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yamao J, Yoshiji Kaneko M, Namisaki T, Takaya H, Mori H,	2019. 3.	Hepatol Res.	49(3):284-295	
Calcified mucinous adenocarcinoma of stomach metastatic to the iris: an autopsy case report	Kitade M, Okura Y, Seki K, Sato S, Nakanishi K, Kitagawa K, Ozutsumi T, Shimozato N, Kaji K, Otani T, Nakai T	2019. 3.	Journal of Medical Case Reports	13(1):64	
Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection.	Obayashi C, Mitoro A, Yamao J, Yoshiji H, Sato S, Moriya K, Furukawa M, Saikawa S, Namisaki T, Kitade M, Kawaratani H, Kaji K, Takaya H, Shimozato N, Sawada Y, Seki K, Kitagawa K, Akahane T, Mitoro A, Okura Y, Yamao J, Yoshiji H.	2019. 3.	Clin Mol Hepatol.	25(1):65-73	
ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma.	Takaya H, Namisaki T, Shimozato N, Kaji K, Kitade M, Moriya K, Sato S, Kawaratani H, Akahane T, Matsumoto M, Yoshiji H.	2019. 5.15	World J Gastrointest Oncol.	11(5):424-435	
Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient L-Amino-Acid-Defined Diet-Induced Murine Model.	Nakanishi K, Kaji K, Kitade M, Kubo T, Furukawa M, Saikawa S, Shimozato N, Sato S, Seki K, Kawaratani H, Moriya K, Namisaki T, Yoshiji H.	2019. 6. 3	Int J Mol Sci	20(11). pii: E2724	学位論文
Blocking development of liver fibrosis augments hepatic progenitor cell-derived liver regeneration in a mouse chronic hepatitis model.	Kitade M, Kaji K, Nishimura N, Seki K, Nakanishi K, Tsuji Y, Sato S, Saikawa S, Takaya H, Kawaratani H, Namisaki T, Moriya K, Mitoro A, Yoshiji H.	2019. 9.	Hepatol Res.	49(9):1034-1045	
Identification of clinical risk factors for histological progression of primary biliary cholangitis	Fujinaga Y, Namisaki T, Moriya K, Kitade M, Kawaratani H, Shimozato N, Kaji K, Takaya H, Sawada Y, Seki K, Akahane T, Okura Y, Sato S, Saikawa S, Nakanishi K, Kubo T, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Mashitani T, Shimozato N, Namisaki T, Kaji K, Kitade M,	2019. 9.	Hepatol Res.	49(9):1015-1025	
Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis.	Okura Y, Sato S, Moriya K, Seki K, Kawaratani H, Takaya H, Sawada Y, Saikawa S, Nakanishi K, Furukawa M, Fujinaga Y, Kubo T, Asada K, Kitagawa K, Tsuji Y, Kaya D, Ozutsumi T, Akahane T, Takaya H, Namisaki T, Kitade M, Kaji K,	2019.10	Hepatol Res.	49(10):1147-1161	
VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.	Nakanishi K, Tsuji Y, Shimozato N, Moriya K, Seki K, Sawada Y, Saikawa S, Sato S, Kawaratani H, Akahane T, Noguchi R, Matsumoto M, Yoshiji H.	2019.10	BMC Gastroenterol	19(1):167	
Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients.	Takaya H, Namisaki T, Kitade M, Shimozato N, Kaji K, Tsuji Y, Nakanishi K, Noguchi R, Fujinaga Y, Sawada Y, Saikawa S, Sato S, Kawaratani H, Moriya K,	2019.10.15	World J Gastrointest Oncol.	11(10):887-897	

Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of	Uzutsumi T, Namisaki T, Shimozato N, Kaji K, Tsuji Y, Kaya D, Fujinaga Y, Furukawa M, Nakanishi K, Sato S, Sawada Y, Saikawa S, Kitagawa K, Takaya H, Kawaratani H, Kitade M, Moriya K, Noguchi R, Akahane T, Mitoro A, Yoshiji H, Furukawa M, Moriya K, Nakayama J, Inoue	2020. 3.21	Int J Mol Sci.	21(6). pii: E2164.		
Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis	T, Momoda R, Kawaratani H, Namisaki T, Sato S, Douhara A, Kaji K, Kitade M, Shimozato N, Sawada Y, Saikawa S, Takaya H, Kitagawa K, Akahane T, Mitoro A, Yamao J, Tanaka Y, Yoshiji H,	2020. 6.	Hepatol Res.	50(7):840-852.		
Hydralazine Sensitizes the Antifibrotic Effect of 5-Aza-2'-deoxycytidine in Hepatic Stellate Cells	Asada K, Kaji K, Sato S, Seki K, Shimozato N, Kawaratani H, Takaya H, Sawada Y, Nakanishi K, Furukawa M, Kitade M, Moriya K, Namisaki T, Noguchi R, Akahane T,	2020. 6.	MDPI			
Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic	Noguchi R, Kaji K, Namisaki T, Moriya K, Kawaratani H, Kitade M, Takaya H, Aihara Y, Douhara A, Asada K, Nishimura N, Miyata T, Yoshiji H	2020. 7. 3	MOLECULAR MEDICINE REPORTS			